Vaccination Granuloma Itch Treated with Capsaicin 8% Patches

Stine HOFFMANN¹,² and Jesper ELBERLING²
¹National Allergy Research Centre, and ²Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Gentofte Hospitalsvej 20A, 1st floor, DK-2900 Hellerup, Denmark. E-mail: stine.hoffmann@regionh.dk
Accepted Nov 4, 2020; Epub ahead of print Nov 10, 2020

Granulomas as an adverse effect following subcutaneous immunotherapy (SCIT) or immunization with other aluminium-adsorbed vaccines has been described since the 1980s (1–3). Despite the overall benign nature of aluminium granulomas, they can cause aggravating itch, and lead to reduced quality of life and discontinuation of both common childhood vaccination programmes and SCIT (4). An effective treatment is yet to be established. We present here a case of, to our knowledge, the first treatment attempt for itching granulomas with capsaicin-patches, which had a successful outcome.

CASE REPORT

A 48-year old female was referred to our department with a medical history of multiple IgE allergies, rhinoconjunctivitis, asthma and eczema.

During childhood she had received treatment with multiple SCIT injections against birch and grass pollen on both lower arms. SCIT was discontinued due to multiple local subcutaneous nodules causing aggravating itch. All former granulomas had disappeared, but her lower arms were still covered with scars and hyperpigmentation following years of scratching. She was patch-tested in 2015 with aluminium chloride hexahydrate 2% pet. and an empty Finn Chamber (Epitest, Tuusula, Finland). Patch-tests were applied for 2 days and read on days 2, 4 and 7 according to recommendations. The test results were negative.

Due to severe respiratory allergy, SCIT injections were resumed, this time on both upper arms. Again, the patient developed local reactions with small itching subcutaneous nodules causing scratch marks and hyperpigmentation, and finally SCIT treatment was terminated, and sublingual immunotherapy was initiated, but the multiple nodules on both upper arms were still severely itching. No flare of itch was seen in the former granulomas on the lower arms. Treatment with antihistamine and topical corticosteroids were not effective. Intra-granuloma injections with triamcinolone acetonide had some effect, but this treatment was not feasible due to the large number of granulomas. Topical capsaicin cream 0.025% was applied 2–4 times daily for 5 weeks and had a positive, but not sufficiently large, effect.

In April 2018, the patient received the first off-label treatment with a Qutenza® 8% capsaicin patch. On her right upper arm, the area with touch-evoked itch (alloknesis) was identified and marked with a pen. The patch was cut with a pair of scissors to cover the area and applied for 1 h under bandage occlusion. After removal, the area was wiped with a cleansing gel and washed with water (Fig. 1).

Mean daily itch severity was evaluated using a visual analogue scale (VAS) with 0 as “no itch” and 10 as “worst imaginable itch” (Fig. 2). Before initiation of Qutenza® treatment, the itch was graded as VAS 8 on both arms. Six weeks after the first treatment, itch was unaffected, i.e. VAS 8, on the untreated arm and was reduced to VAS 4 on the treated arm. VAS 4 is described by the patient as several daily disturbances by itch, where scratching or pinching is necessary.

Due to the perceived effectiveness of the Qutenza® patch lasting 2–3 months, treatment was repeated on both arms every third month, with VAS scores gradually reducing. Except for erythema and a burning sensation during treatment, and increased sensitivity to touch, heat and sun exposure, normalizing within 3–4 days, no other adverse effects were seen.
DISCUSSION

Qutenza® (Grünenthal GmbH, Aachen, Germany) is a capsaicin 8% topical patch mainly used for the treatment of neuropathic pain (5, 6). Recently the use of Qutenza® patches has been expanded to include neuropathic itch (7). The patches deliver a high concentration of synthetic capsaicin, which works as a transient receptor potential vanilloid-1 (TRPV-1) agonist. When applying the patch, the local cutaneous nociceptors are activated, leading to pain and erythema, and following exposure there is a desensitization, which causes the itch-relieving effect. Side-effects of Qutenza® are mainly application-site erythema and pain, which can be quite significant and necessitate use of pain-relieving medication during the application.

Itching subcutaneous granulomas are mostly seen in children; 1% develop granulomas following vaccination with aluminium-adsorbed vaccines (8). The clinical presentation of subcutaneous granulomas is usually a firm nodule on the injection site, with associated pruritus. Hypertrichosis and hyperpigmentation are also common (4, 8).

Of all children with vaccination granulomas, 95% become hypersensitized against aluminium (3). Aluminium contact allergy has also been described in older children and adults undergoing SCIT (1, 2). The current patient was patch-tested in 2015, with a negative result. However, this was prior to resumption of her SCIT treatment, and the granulomas on her lower arms from SCIT treatments in childhood were asymptomatic. This correlates with the fact that aluminium contact allergy and the granulomas are known to diminish over time (9, 10).

Because the current patient was still symptomatic, a patch-test was performed again in September 2020 with aluminium chloride hexahydrate 2% pet. and an empty patch-test was performed again in September 2020 with aluminium chloride hexahydrate 2% pet. and an empty

There are limited treatment options for achieving relief of itch in patients with itching subcutaneous granulomas. In the current patient, Qutenza® treatment significantly reduced the itch in both intensity and area, respectively. Pretreatment with lidocaine (4%) or lidocaine (2.5%)/prilocaine (2.5%) may be used prior to the application, as suggested by the manufacturer, to sooth the skin prior to applying the patches (7). This could lead to more patients with granulomas undergoing this treatment. If capsaicin treatment in children is considered, capsaicin cream 0.025%, applied twice daily for 6 weeks, could be a safer regimen than capsaicin patches. Treatment of children is delicate, and applying an 8% capsaicin patch should be considered with caution until further studies on adults have been completed.

ACKNOWLEDGEMENT

Funding. The Danish Environmental Protection Agency; a grant to the National Allergy Research Centre.

The authors have no conflict of interest to declare.

REFERENCES

1. Clemmensen O, Knudsen HE. Contact sensitivity to aluminium in a patient hypersensitized with aluminium precipitated grass pollen. Contact Dermatitis 1980; 6: 305–308.
2. Netterlid E, Hindén M, Siemund I, Björk J, Werner S, Jacobsson H, et al. Does allergen-specific immunotherapy induce contact allergy to aluminium? Acta Derm Venereol 2013; 93: 50–56.
3. Bergfors E, Trollfors B, Inerot A. Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer. Vaccine 2003; 22: 64–69.
4. Hoffmann SS, Thysen JP, Elberling J, Hansen KS, Johansen JD. Children with vaccination granulomas and aluminium contact allergy: evaluation of predispositions, avoided behavior, and quality of life. Contact Dermatitis 2020; 83: 99–107.
5. Mou J, Paillard F, Turnbull B, Trudeau J, Stoker M, Katz NP. Efficacy of Qutenza® (capsaicin) 8% patch for neuropathic pain: a meta-analysis of the Qutenza Clinical Trials Database. Pain 2013; 154: 1632–1639.
6. Weisshaar E, Szepeitowski JC, Dalgard F, Gascovich S, Gießer U, Gimenez-Arnau A, et al. European S2k Guideline on chronic pruritus. Acta Derm Venereol 2019; 99: 569–506.
7. Andersen HH, Arendt-Nielsen L, Elberling J. Topical capsaicin 8% for the treatment of neuropathic itch conditions. Clin Exp Dermatol 2017; 42: 596–598.
8. Bergfors E, Trollfors B. Sixty-four children with persistent itching nodules and contact allergy to aluminium after vaccination with aluminium-adsorbed vaccines – prognosis and outcome after booster vaccination. Eur J Pediatr 2013; 172: 171–177.
9. Gente Lidholm A, Bergfors E, Inerot A, Blomgren U, Gillstedt M, Trollfors B. Unexpected loss of contact allergy to aluminium induced by vaccine. Contact Dermatitis 2013; 68: 286–292.
10. Siemund I, Mowitz M, Zimerson E, Bruze M, Hindén M. Variation in aluminium patch test reactivity over time. Contact Dermatitis 2017; 77: 288–296.
11. Bruze M, Lundh K, Gruvberger B, Hindén M. Aluminium chloride hexahydrate at 2% is insufficient to trace contact allergy to aluminium. Contact Dermatitis 2008; 59: 183–184.